<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>INSPRA- eplerenone tablet </strong><br>Rebel Distributors Corp<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use INSPRA safely and effectively. See full prescribing information for INSPRA.<br> <br>INSPRA (eplerenone) tablet for oral use<br>Initial U.S. Approval: 2002</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">INSPRA is an aldosterone antagonist indicated for: </p>
<ul>
<li>Improving survival of stable patients with LV systolic dysfunction (LVEF ≤40%) and CHF after an <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span>. (<a href="#i4i_section_id_f6637d73-1274-4bc9-817d-9c87435d708d">1.2</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>, alone or combined with other agents. (<a href="#i4i_section_id_79eeddaf-62cc-4f6a-b3d3-0bcba35121aa">1.3</a>)</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta"><span class="Underline"><span class="Italics">CHF Post-MI</span></span>: Initiate treatment with 25 mg once daily. Titrate to maximum of 50 mg once daily within 4 weeks, as tolerated. Dose adjustments may be required based on potassium levels. (<a href="#i4i_section_id_36d8833d-3b8b-4482-8033-776f3a3b8532">2.1</a>) </p>
<p class="Highlighta"><span class="Underline"><span class="Italics"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></span></span>: 50 mg once daily, alone or combined with other antihypertensive agents. For inadequate response, increase to 50 mg twice daily. Higher dosages are not recommended. (<a href="#i4i_section_id_b00ac079-9cf2-4bd5-aa2b-fce0ecf6b760">2.2</a>) </p>
<p class="Highlighta"><span class="Underline"><span class="Italics">For all patients:</span></span> </p>
<p class="Highlighta">Measure serum potassium before starting INSPRA and periodically thereafter. (<a href="#i4i_section_id_882d2422-4c98-4c3a-95f2-5494d2b8c08e">2.3</a>) </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Tablets: 25 mg, 50 mg (<a href="#i4i_dosage_form_strength_id_a3d6dc2e-e52d-416e-b4ca-82b3ff5ef05c">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div>
<p class="Highlighta"><span class="Underline"><span class="Italics">For all patients:</span></span> </p>
<ul>
<li>Serum potassium &gt;5.5 mEq/L at initiation (<a href="#i4i_contraindications_id_3759c222-e2a9-4c12-9ab7-bb72e45246fa">4</a>)</li>
<li>Creatinine clearance ≤30 mL/min (<a href="#i4i_contraindications_id_3759c222-e2a9-4c12-9ab7-bb72e45246fa">4</a>)</li>
<li>Concomitant use with strong CYP3A4 inhibitors (<a href="#i4i_contraindications_id_3759c222-e2a9-4c12-9ab7-bb72e45246fa">4</a>, <a href="#i4i_section_id_56e7a51c-7887-43b2-bc11-270ad02fbc8e">7.1</a>)</li>
</ul>
<p class="Highlighta"><span class="Underline"><span class="Italics">For the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>:</span></span> </p>
<ul>
<li>Type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> with <span class="product-label-link" type="condition" conceptid="4195061" conceptname="Microalbuminuria">microalbuminuria</span> (<a href="#i4i_contraindications_id_3759c222-e2a9-4c12-9ab7-bb72e45246fa">4</a>)</li>
<li>Serum creatinine &gt;2.0 mg/dL in males, &gt;1.8 mg/dL in females (<a href="#i4i_contraindications_id_3759c222-e2a9-4c12-9ab7-bb72e45246fa">4</a>)</li>
<li>Creatinine clearance &lt;50 mL/min (<a href="#i4i_contraindications_id_3759c222-e2a9-4c12-9ab7-bb72e45246fa">4</a>)</li>
<li>Concomitant use of potassium supplements or potassium-sparing diuretics (<a href="#i4i_contraindications_id_3759c222-e2a9-4c12-9ab7-bb72e45246fa">4</a>)</li>
</ul>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul><li><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span>: Patients with decreased renal function and diabetics with <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span> are at increased risk. Proper patient selection and monitoring and avoiding certain concomitant medications can minimize the risk. (<a href="#i4i_section_id_66863df8-b8b2-46a7-8294-c1e32d7ae018">5.1</a>)</li></ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta"><span class="Underline"><span class="Italics">CHF Post-MI</span></span>: Most common adverse reactions (&gt;2% and more frequent than with placebo): <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> and increased creatinine. (<a href="#i4i_section_id_c72b4273-0467-43a2-a754-3715220785bc">6.1</a>) </p>
<p class="Highlighta"><span class="Underline"><span class="Italics"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></span></span>: Most common adverse reactions (≥2% and more frequent than with placebo): <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> and flu-like symptoms. (<a href="#i4i_section_id_c72b4273-0467-43a2-a754-3715220785bc">6.1</a>) </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</span> </p>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul><li>CYP3A4 Inhibitors: Reduce the starting dose for <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> to 25 mg once daily when used with moderate CYP3A4 inhibitors (e.g., verapamil, erythromycin, saquinavir, fluconazole). (<a href="#i4i_section_id_a074659c-24b7-43cc-9f10-f0ed8f528c4f">2.4</a>, <a href="#i4i_section_id_56e7a51c-7887-43b2-bc11-270ad02fbc8e">7.1</a>, <a href="#i4i_pharmacokinetics_id_754212d6-10e5-4958-9297-c885f1e9bcc2">12.3</a>)</li></ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div><div></div></div>
<div>
<div><div></div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 8/2009</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Patient Selection Considerations</a></h2>
<h2><a href="#section-1.2" class="toc">1.2 <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> Post-<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></a></h2>
<h2><a href="#section-1.3" class="toc">1.3 <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> Post-<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></a></h2>
<h2><a href="#section-2.2" class="toc">2.2 <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Recommended Monitoring</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Dose Modifications for Specific Populations</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span> </a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Impaired Hepatic Function</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Clinical Laboratory Test Findings </a></h2>
<h2><a href="#section-6.3" class="toc">6.3 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 CYP3A4 Inhibitors</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 ACE Inhibitors and Angiotensin II Receptor Antagonists</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Lithium</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> Post-<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></a></h2>
<h2><a href="#section-13.2" class="toc">14.2 <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> </a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_27605329-7f67-43f3-9e96-6d6e3ca2d72f"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f93fea3c-9e76-4759-869f-48f3bd5c3a65"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Patient Selection Considerations</h2>
<p class="First">Serum potassium levels should be measured before initiating INSPRA therapy, and INSPRA should not be prescribed if serum potassium is &gt;5.5 mEq/L. <span class="Italics">[See <a href="#i4i_contraindications_id_3759c222-e2a9-4c12-9ab7-bb72e45246fa">CONTRAINDICATIONS (4)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f6637d73-1274-4bc9-817d-9c87435d708d"></a><a name="section-1.2"></a><p></p>
<h2>1.2 <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> Post-<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></h2>
<p class="First">INSPRA is indicated to improve survival of stable patients with left ventricular (LV) systolic dysfunction (<span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> ≤40%) and clinical evidence of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> (CHF) after an <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span> (MI).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_79eeddaf-62cc-4f6a-b3d3-0bcba35121aa"></a><a name="section-1.3"></a><p></p>
<h2>1.3 <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></h2>
<p class="First">INSPRA is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. INSPRA may be used alone or in combination with other antihypertensive agents.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_e0b55fee-5aa8-4a34-b416-270ea8f8bb54"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_36d8833d-3b8b-4482-8033-776f3a3b8532"></a><a name="section-2.1"></a><p></p>
<h2>2.1 <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> Post-<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></h2>
<p class="First">Treatment should be initiated at 25 mg once daily and titrated to the recommended dose of 50 mg once daily, preferably within 4 weeks as tolerated by the patient. INSPRA may be administered with or without food. </p>
<p> Once treatment with INSPRA has begun, adjust the dose based on the serum potassium level as shown in Table 1.</p>
<a name="id_1bfb2d4a-f1aa-4d27-a036-124f4d20182e"></a><table>
<caption><span>Table 1. Dose Adjustment in <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> Post-MI</span></caption>
<col align="center" width="15%">
<col align="center" width="15%">
<col align="left" width="60%">
<thead><tr class="Botrule First Last">
<td class="Lrule Rrule" align="left" valign="top">Serum Potassium<br>(mEq/L)</td>
<td class="Rrule" align="left" valign="top">Action</td>
<td class="Rrule" align="center" valign="top">Dose Adjustment</td>
</tr></thead>
<tbody>
<tr class="First Toprule">
<td class="Lrule Rrule" align="left" valign="top">&lt; 5.0</td>
<td class="Rrule" align="left" valign="top">Increase</td>
<td class="Rrule" align="left" valign="top">25 mg every other day to 25 mg once daily<br>25 mg once daily to 50 mg once daily</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">5.0–5.4</td>
<td class="Rrule" align="left" valign="top">Maintain</td>
<td class="Rrule" align="left" valign="top">No adjustment</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">5.5–5.9</td>
<td class="Rrule" align="left" valign="top">Decrease</td>
<td class="Rrule" align="left" valign="top">50 mg once daily to 25 mg once daily<br>25 mg once daily to 25 mg every other day<br>25 mg every other day to withhold</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left" valign="top">≥ 6.0</td>
<td class="Rrule" align="left" valign="top">Withhold</td>
<td class="Rrule" align="left" valign="top">Restart at 25 mg every other day when potassium levels <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> to &lt;5.5 mEq/L</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b00ac079-9cf2-4bd5-aa2b-fce0ecf6b760"></a><a name="section-2.2"></a><p></p>
<h2>2.2 <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></h2>
<p class="First">The recommended starting dose of INSPRA is 50 mg administered once daily. The full therapeutic effect of INSPRA is apparent within 4 weeks. For patients with an inadequate blood pressure response to 50 mg once daily the dosage of INSPRA should be increased to 50 mg twice daily. Higher dosages of INSPRA are not recommended because they have no greater effect on blood pressure than 100 mg and are associated with an increased risk of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>. <span class="Italics">[See <a href="#i4i_section_id_33617a91-f383-4d7e-9018-78fbd92ebadf">CLINICAL STUDIES (14.2)</a>.]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_882d2422-4c98-4c3a-95f2-5494d2b8c08e"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Recommended Monitoring</h2>
<p class="First">Serum potassium should be measured before initiating INSPRA therapy, within the first week, and at one month after the start of treatment or dose adjustment. Serum potassium should be assessed periodically thereafter. Patient characteristics and serum potassium levels may indicate that additional monitoring is appropriate. <span class="Italics">[See <a href="#i4i_section_id_66863df8-b8b2-46a7-8294-c1e32d7ae018">WARNINGS AND PRECAUTIONS (5.1)</a>, <a href="#i4i_section_id_a657f886-b386-4506-ab4b-d22fae49064d">ADVERSE REACTIONS (6.2)</a>.]</span> In the EPHESUS study <span class="Italics">[See <a href="#i4i_section_id_af8b703d-4a19-40aa-9128-58e7273e26dc">CLINICAL STUDIES (14.1)</a>]</span>, the majority of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> was observed within the first three months after randomization. </p>
<p>In all patients taking INSPRA who start taking a moderate CYP3A4 inhibitor, check serum potassium and serum creatinine in 3–7 days.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a074659c-24b7-43cc-9f10-f0ed8f528c4f"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Dose Modifications for Specific Populations</h2>
<p class="First">For hypertensive patients receiving moderate CYP3A4 inhibitors (e.g., erythromycin, saquinavir, verapamil, and fluconazole), the starting dose of INSPRA should be reduced to 25 mg once daily. <span class="Italics">[See <a href="#i4i_section_id_56e7a51c-7887-43b2-bc11-270ad02fbc8e">DRUG INTERACTIONS (7.1)</a>.]</span></p>
<p>No adjustment of the starting dose is recommended for the elderly or for patients with mild-to-moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. <span class="Italics">[See <a href="#i4i_pharmacokinetics_id_754212d6-10e5-4958-9297-c885f1e9bcc2">CLINICAL PHARMACOLOGY (12.3)</a>.]</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_a3d6dc2e-e52d-416e-b4ca-82b3ff5ef05c"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<ul>
<li>25 mg tablets: yellow diamond biconvex film-coated tablets debossed with <span class="Italics">Pfizer</span> on one side and <span class="Italics">NSR</span> over <span class="Italics">25</span> on the other</li>
<li>50 mg tablets: yellow diamond biconvex film-coated tablets debossed with <span class="Italics">Pfizer</span> on one side and <span class="Italics">NSR</span> over <span class="Italics">50</span> on the other</li>
</ul>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_3759c222-e2a9-4c12-9ab7-bb72e45246fa"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3e0eba3b-404d-47f8-b62f-5c11cd7a4fee"></a><a name="section-4.1"></a><p></p>
<p class="First"><span class="Underline"><span class="Italics">For All Patients</span></span></p>
<p>INSPRA is contraindicated in all patients with:</p>
<ul>
<li>serum potassium &gt;5.5 mEq/L at initiation,</li>
<li>creatinine clearance ≤30 mL/min, or</li>
<li>concomitant administration of strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, and nelfinavir). <span class="Italics">[See <a href="#i4i_section_id_56e7a51c-7887-43b2-bc11-270ad02fbc8e">DRUG INTERACTIONS (7.1)</a>, <a href="#i4i_pharmacokinetics_id_754212d6-10e5-4958-9297-c885f1e9bcc2">CLINICAL PHARMACOLOGY (12.3)</a>.]</span>
</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8ec0f7cf-094d-4cc4-999e-70e3569b09c5"></a><a name="section-4.2"></a><p></p>
<p class="First"><span class="Underline"><span class="Italics">For Patients Treated for <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></span></span></p>
<p>INSPRA is contraindicated for the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> in patients with:</p>
<ul>
<li>type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> with <span class="product-label-link" type="condition" conceptid="4195061" conceptname="Microalbuminuria">microalbuminuria</span>,</li>
<li>serum creatinine &gt;2.0 mg/dL in males or &gt;1.8 mg/dL in females,</li>
<li>creatinine clearance &lt;50 mL/min, or</li>
<li>concomitant administration of potassium supplements or potassium-sparing diuretics (e.g., amiloride, spironolactone, or triamterene). <span class="Italics">[See <a href="#i4i_section_id_66863df8-b8b2-46a7-8294-c1e32d7ae018">WARNINGS AND PRECAUTIONS (5.1)</a>, <a href="#i4i_section_id_a657f886-b386-4506-ab4b-d22fae49064d">ADVERSE REACTIONS (6.2)</a>, <a href="#i4i_interactions_id_e09b17af-a954-4441-943f-944969816a00">DRUG INTERACTIONS (7)</a>, and <a href="#i4i_pharmacokinetics_id_754212d6-10e5-4958-9297-c885f1e9bcc2">CLINICAL PHARMACOLOGY (12.3)</a>.]</span>
</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_b0002ab9-7cac-4e34-a69e-7d7c692d23dd"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_66863df8-b8b2-46a7-8294-c1e32d7ae018"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span> </h2>
<p class="First">Minimize the risk of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> with proper patient selection and monitoring, and avoidance of certain concomitant medications <span class="Italics">[See <a href="#i4i_contraindications_id_3759c222-e2a9-4c12-9ab7-bb72e45246fa">CONTRAINDICATIONS (4)</a>, <a href="#i4i_section_id_a657f886-b386-4506-ab4b-d22fae49064d">ADVERSE REACTIONS (6.2)</a>, and <a href="#i4i_interactions_id_e09b17af-a954-4441-943f-944969816a00">DRUG INTERACTIONS (7)</a>]</span>. Monitor patients for the development of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> until the effect of INSPRA is established. Patients who develop <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> (&gt;5.5 mEq/L) may continue INSPRA therapy with proper dose adjustment. Dose reduction decreases potassium levels. <span class="Italics">[See <a href="#i4i_section_id_36d8833d-3b8b-4482-8033-776f3a3b8532">DOSAGE AND ADMINISTRATION (2.1)</a>.]</span></p>
<p>The rates of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> increase with declining renal function. <span class="Italics">[See <a href="#i4i_section_id_a657f886-b386-4506-ab4b-d22fae49064d">ADVERSE REACTIONS (6.2)</a>.]</span> Patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> who have serum creatinine levels &gt;2.0 mg/dL (males) or &gt;1.8 mg/dL (females) or creatinine clearance ≤50 mL/min should not be treated with INSPRA. <span class="Italics">[See <a href="#i4i_contraindications_id_3759c222-e2a9-4c12-9ab7-bb72e45246fa">CONTRAINDICTIONS (4)</a>.]</span> Patients with CHF post-MI who have serum creatinine levels &gt;2.0 mg/dL (males) or &gt;1.8 mg/dL (females) or creatinine clearance ≤50mL/min should be treated with INSPRA with caution. </p>
<p>Diabetic patients with CHF post-MI should also be treated with caution, especially those with <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>. The subset of patients in the EPHESUS study with both <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> and <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span> on the baseline urinalysis had increased rates of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> compared to patients with either <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>. <span class="Italics">[See <a href="#i4i_section_id_a657f886-b386-4506-ab4b-d22fae49064d">ADVERSE REACTIONS (6.2)</a>.]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3731b60e-e562-46d2-8669-96cb7ec16e38"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Impaired Hepatic Function</h2>
<p class="First">Mild-to-moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> did not increase the incidence of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>. In 16 subjects with mild-to-moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> who received 400 mg of eplerenone, no elevations of serum potassium above 5.5 mEq/L were observed. The mean increase in serum potassium was 0.12 mEq/L in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> and 0.13 mEq/L in normal controls. The use of INSPRA in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> has not been evaluated. <span class="Italics">[See <a href="#i4i_pharmacokinetics_id_754212d6-10e5-4958-9297-c885f1e9bcc2">CLINICAL PHARMACOLOGY (12.3)</a>.]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ded5d2d3-1376-4086-9d69-1776d629972f"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></h2>
<p class="First">Patients with decreased renal function are at increased risk of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>. <span class="Italics">[See <a href="#i4i_contraindications_id_3759c222-e2a9-4c12-9ab7-bb72e45246fa">CONTRAINDICATIONS (4)</a>,<a href="#i4i_section_id_66863df8-b8b2-46a7-8294-c1e32d7ae018">WARNINGS AND PRECAUTIONS (5.1)</a>, <a href="#i4i_section_id_c72b4273-0467-43a2-a754-3715220785bc">ADVERSE REACTIONS (6.1)</a>.]</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_b60f0124-1f2c-4bb1-9422-08800aa327a8"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions are discussed in greater detail in other sections of the labeling:</p>
<ul><li><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span> <span class="Italics">[See <a href="#i4i_section_id_66863df8-b8b2-46a7-8294-c1e32d7ae018">WARNINGS AND PRECAUTIONS (5.1)</a>]</span>
</li></ul>
<p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in practice.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c72b4273-0467-43a2-a754-3715220785bc"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_aee48139-53e4-4a39-b9d7-72480a6dc572"></a><a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Italics"><span class="Underline"><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> Post-<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></span></span></p>
<p>In EPHESUS, safety was evaluated in 3307 patients treated with INSPRA and 3301 placebo-treated patients. The overall incidence of adverse events reported with INSPRA (78.9%) was similar to placebo (79.5%). Adverse events occurred at a similar rate regardless of age, gender, or race. Patients discontinued treatment due to an adverse event at similar rates in either treatment group (4.4% INSPRA vs. 4.3% placebo), with the most common reasons for discontinuation being <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and abnormal renal function.</p>
<p>Adverse reactions that occurred more frequently in patients treated with INSPRA than placebo were <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> (3.4% vs. 2.0%) and increased creatinine (2.4% vs. 1.5%). Discontinuations due to <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> or abnormal renal function were less than 1.0% in both groups. <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> occurred less frequently in patients treated with INSPRA (0.6% vs. 1.6%).</p>
<p>The rates of sex hormone-related adverse events are shown in Table 2.</p>
<a name="id_94a31b15-de8c-43dc-b8ca-bfe2238c5168"></a><table>
<caption><span>Table 2. Rates of Sex Hormone-Related Adverse Events in EPHESUS</span></caption>
<col align="center" width="15%">
<col align="center" width="20%">
<col align="center" width="20%">
<col align="center" width="15%">
<col align="center" width="30%">
<thead>
<tr class="First Toprule">
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" colspan="3" valign="top">Rates in Males</td>
<td class="Botrule Lrule Rrule" align="left" valign="top">Rates in Females</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">Gynecomastia</span></td>
<td class="Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">Mastodynia</span></td>
<td class="Rrule" align="left" valign="top">Either</td>
<td class="Rrule" align="left" valign="top">Abnormal <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal Bleeding</span></td>
</tr>
</thead>
<tbody>
<tr class="First Toprule">
<td class="Lrule Rrule" align="left" valign="top">INSPRA</td>
<td class="Rrule" align="left" valign="top">0.4%</td>
<td class="Rrule" align="left" valign="top">0.1%</td>
<td class="Rrule" align="left" valign="top">0.5%</td>
<td class="Rrule" align="left" valign="top">0.4%</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left" valign="top">Placebo</td>
<td class="Rrule" align="left" valign="top">0.5%</td>
<td class="Rrule" align="left" valign="top">0.1%</td>
<td class="Rrule" align="left" valign="top">0.6%</td>
<td class="Rrule" align="left" valign="top">0.4%</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_efe61fc2-0cf3-4f34-9e9c-0c6199b0c5af"></a><a name="section-6.1.2"></a><p></p>
<p class="First"><span class="Underline"><span class="Italics"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></span></span></p>
<p>INSPRA has been evaluated for safety in 3091 patients treated for <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. A total of 690 patients were treated for over 6 months and 106 patients were treated for over 1 year. </p>
<p>In placebo-controlled studies, the overall rates of adverse events were 47% with INSPRA and 45% with placebo. Adverse events occurred at a similar rate regardless of age, gender, or race. Therapy was discontinued due to an adverse event in 3% of patients treated with INSPRA and 3% of patients given placebo. The most common reasons for discontinuation of INSPRA were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>/<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and increased GGT. The adverse events that were reported at a rate of at least 1% of patients and at a higher rate in patients treated with INSPRA in daily doses of 25 to 400 mg versus placebo are shown in Table 3. </p>
<a name="id_15dd9963-dbb8-4175-aa4a-b2ba9f99b405"></a><table>
<caption><span>Table 3. Rates (%) of Adverse Events Occurring in Placebo-Controlled <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> Studies in ≥1% of Patients Treated with INSPRA (25 to 400 mg) and at a More Frequent Rate than in Placebo-Treated Patients</span></caption>
<col align="left" width="50%">
<col align="center" width="25%">
<col align="center" width="25%">
<thead><tr class="Botrule First Last">
<td class="Lrule Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top">INSPRA<br>(n=945)</td>
<td class="Rrule" align="left" valign="top">Placebo<br>(n=372)</td>
</tr></thead>
<tfoot><tr class="Last"><td class="Lrule Rrule" align="left" colspan="3" valign="top">Note: Adverse events that are too general to be informative or are very common in the treated population are excluded.</td></tr></tfoot>
<tbody>
<tr class="First Toprule">
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Metabolic</span></td>
<td class="Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="437827" conceptname="Pure hypercholesterolemia">Hypercholesterolemia</span></td>
<td class="Rrule" align="left" valign="top">1</td>
<td class="Rrule" align="left" valign="top">0</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">Hypertriglyceridemia</span></td>
<td class="Rrule" align="left" valign="top">1</td>
<td class="Rrule" align="left" valign="top">0</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Digestive</span></td>
<td class="Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Rrule" align="left" valign="top">2</td>
<td class="Rrule" align="left" valign="top">1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></td>
<td class="Rrule" align="left" valign="top">1</td>
<td class="Rrule" align="left" valign="top">0</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Urinary</span></td>
<td class="Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="4168705" conceptname="Albuminuria">Albuminuria</span></td>
<td class="Rrule" align="left" valign="top">1</td>
<td class="Rrule" align="left" valign="top">0</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Respiratory</span></td>
<td class="Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Coughing</span></td>
<td class="Rrule" align="left" valign="top">2</td>
<td class="Rrule" align="left" valign="top">1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Central/Peripheral Nervous System</span></td>
<td class="Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Rrule" align="left" valign="top">3</td>
<td class="Rrule" align="left" valign="top">2</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="Bold">Body as a Whole</span></td>
<td class="Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Rrule" align="left" valign="top">2</td>
<td class="Rrule" align="left" valign="top">1</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span>-like symptoms</td>
<td class="Rrule" align="left" valign="top">2</td>
<td class="Rrule" align="left" valign="top">1</td>
</tr>
</tbody>
</table>
<p><span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">Gynecomastia</span> and abnormal <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> were reported with INSPRA but not with placebo. The rates of these sex hormone-related adverse events are shown in Table 4. The rates increased slightly with increasing duration of therapy. In females, abnormal <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> was also reported in 0.8% of patients on antihypertensive medications (other than spironolactone) in active control arms of the studies with INSPRA.</p>
<a name="id_b9c7b338-fae7-478f-96ea-83decfea7a1b"></a><table>
<caption><span>Table 4. Rates of Sex Hormone-Related Adverse Events with INSPRA in <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> Clinical Studies</span></caption>
<col align="left" width="25%">
<col align="center" width="20%">
<col align="center" width="20%">
<col align="center" width="15%">
<col align="center" width="20%">
<thead>
<tr class="First Toprule">
<td class="Botrule Lrule Rrule" align="left" rowspan="2" valign="top"></td>
<td class="Botrule Rrule" align="left" colspan="3" valign="top">Rates in Males</td>
<td class="Botrule Lrule Rrule" align="left" valign="top">Rates in Females</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="center" valign="top"><span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">Gynecomastia</span></td>
<td class="Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">Mastodynia</span></td>
<td class="Rrule" align="left" valign="top">Either</td>
<td class="Rrule" align="left" valign="top">Abnormal <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal Bleeding</span></td>
</tr>
</thead>
<tbody>
<tr class="First Toprule">
<td class="Lrule Rrule" align="left" valign="top">All controlled studies</td>
<td class="Rrule" align="left" valign="top">0.5%</td>
<td class="Rrule" align="left" valign="top">0.8%</td>
<td class="Rrule" align="left" valign="top">1.0%</td>
<td class="Rrule" align="left" valign="top">0.6%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Controlled studies lasting ≥ 6 months </td>
<td class="Rrule" align="left" valign="top">0.7%</td>
<td class="Rrule" align="left" valign="top">1.3%</td>
<td class="Rrule" align="left" valign="top">1.6%</td>
<td class="Rrule" align="left" valign="top">0.8%</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left" valign="top">Open-label, long-term study</td>
<td class="Rrule" align="left" valign="top">1.0%</td>
<td class="Rrule" align="left" valign="top">0.3%</td>
<td class="Rrule" align="left" valign="top">1.0%</td>
<td class="Rrule" align="left" valign="top">2.1%</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a657f886-b386-4506-ab4b-d22fae49064d"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Clinical Laboratory Test Findings </h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ae9afccf-5085-4f5e-915e-26fb007ab595"></a><a name="section-6.2.1"></a><p></p>
<p class="First"><span class="Underline"><span class="Italics"><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> Post-<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></span></span></p>
<p><span class="Bold">Creatinine:</span> Increases of more than 0.5 mg/dL were reported for 6.5% of patients administered INSPRA and for 4.9% of placebo-treated patients. </p>
<p><span class="Bold">Potassium:</span> In EPHESUS <span class="Italics">[see <a href="#i4i_section_id_af8b703d-4a19-40aa-9128-58e7273e26dc">CLINICAL STUDIES (14.1)</a>]</span>, the frequencies of patients with changes in potassium (&lt;3.5 mEq/L or &gt;5.5 mEq/L or ≥6.0 mEq/L) receiving INSPRA compared with placebo are displayed in Table 5.</p>
<a name="id_d61e1836-0645-4f8e-9344-152d1703959e"></a><table>
<caption><span>Table 5. <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> (&lt;3.5 mEq/L) or <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span> (&gt;5.5 or ≥6.0 mEq/L) in EPHESUS</span></caption>
<col align="left" width="33%">
<col align="center" width="34%">
<col align="center" width="33%">
<thead><tr class="Botrule First Last">
<td class="Lrule Rrule" align="left" valign="top">Potassium (mEq/L)</td>
<td class="Rrule" align="left" valign="top">INSPRA<br>(N=3251)<br>n (%)</td>
<td class="Rrule" align="left" valign="top">Placebo<br>(N=3237)<br>n (%)</td>
</tr></thead>
<tbody>
<tr class="First Toprule">
<td class="Lrule Rrule" align="left" valign="top">&lt; 3.5</td>
<td class="Rrule" align="left" valign="top">273 (8.4)</td>
<td class="Rrule" align="left" valign="top">424 (13.1)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">&gt;5.5</td>
<td class="Rrule" align="left" valign="top">508 (15.6)</td>
<td class="Rrule" align="left" valign="top">363 (11.2)</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left" valign="top">≥ 6.0</td>
<td class="Rrule" align="left" valign="top">180 (5.5)</td>
<td class="Rrule" align="left" valign="top">126 (3.9)</td>
</tr>
</tbody>
</table>
<p>Table 6 shows the rates of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> in EPHESUS as assessed by baseline renal function (creatinine clearance). </p>
<a name="id_625cd0fb-8d33-4f00-929b-91c66a36da7d"></a><table>
<caption><span>Table 6. Rates of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span> ( &gt;5.5 mEq/L) in EPHESUS by Baseline Creatinine Clearance<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></span></caption>
<col align="left" width="40%">
<col align="center" width="20%">
<col align="center" width="20%">
<thead><tr class="Botrule First Last">
<td class="Lrule Rrule" align="left" valign="top">Baseline Creatinine Clearance</td>
<td class="Rrule" align="left" valign="top">INSPRA<br>(N=508)<br>n (%)</td>
<td class="Rrule" align="left" valign="top">Placebo<br>(N=363)<br>n (%)</td>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Estimated using the Cockroft-Gault formula.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First Toprule">
<td class="Lrule Rrule" align="left" valign="top">≤30 mL/min</td>
<td class="Rrule" align="left" valign="top">160 (32)</td>
<td class="Rrule" align="left" valign="top">82 (23)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">31–50 mL/min</td>
<td class="Rrule" align="left" valign="top">122 (24)</td>
<td class="Rrule" align="left" valign="top">46 (13)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">51–70 mL/min</td>
<td class="Rrule" align="left" valign="top">86 (17)</td>
<td class="Rrule" align="left" valign="top">48 (13)</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left" valign="top">&gt;70 mL/min</td>
<td class="Rrule" align="left" valign="top">56 (11)</td>
<td class="Rrule" align="left" valign="top">32 (9)</td>
</tr>
</tbody>
</table>
<p>Table 7 shows the rates of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> in EPHESUS as assessed by two baseline characteristics: presence/absence of <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span> from baseline urinalysis and presence/absence of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. <span class="Italics">[See <a href="#i4i_section_id_66863df8-b8b2-46a7-8294-c1e32d7ae018">WARNINGS AND PRECAUTIONS (5.1)</a>.]</span></p>
<a name="id_d7e6619e-0a69-48cd-9c66-5aa8b434b518"></a><table>
<caption><span>Table 7. Rates of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span> ( &gt;5.5 mEq/L) in EPHESUS by <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">Proteinuria</span> and History of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span><a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a></span></caption>
<col align="left" width="40%">
<col align="center" width="20%">
<col align="center" width="20%">
<thead><tr class="Botrule First Last">
<td class="Lrule Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top">INSPRA<br>(N=508)<br>n (%)</td>
<td class="Rrule" align="left" valign="top">Placebo<br>(N=363)<br>n (%)</td>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> assessed as positive medical history at baseline; <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span> assessed by positive dipstick urinalysis at baseline.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First Toprule">
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">Proteinuria</span>, no <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> </td>
<td class="Rrule" align="left" valign="top">81 (16)</td>
<td class="Rrule" align="left" valign="top">40 (11)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span>, no <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">Proteinuria</span></td>
<td class="Rrule" align="left" valign="top">91 (18)</td>
<td class="Rrule" align="left" valign="top">47 (13)</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">Proteinuria</span> and <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span></td>
<td class="Rrule" align="left" valign="top">132 (26)</td>
<td class="Rrule" align="left" valign="top">58 (16)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_eb3b5e95-8725-4602-a4a8-05f1532a7222"></a><a name="section-6.2.2"></a><p></p>
<p class="First"><span class="Underline"><span class="Italics"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></span></span></p>
<p><span class="Bold">Potassium:</span> In placebo-controlled fixed-dose studies, the mean increases in serum potassium were dose-related and are shown in Table 8 along with the frequencies of values &gt;5.5 mEq/L.</p>
<a name="id_9a4e2e10-5ca7-4ca1-8e7a-565d9f1e765e"></a><table>
<caption><span>Table 8. Increases in Serum Potassium in the Placebo-Controlled, Fixed-Dose <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> Studies of INSPRA</span></caption>
<col align="center" width="20%">
<col align="center" width="20%">
<col align="center" width="30%">
<col align="center" width="30%">
<thead>
<tr class="First Toprule">
<td class="Botrule Lrule Rrule" align="left" colspan="2" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top">Mean Increase mEq/L</td>
<td class="Botrule Lrule Rrule" align="left" valign="top">% &gt;5.5 mEq/L</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left" valign="top">Daily Dosage</td>
<td class="Rrule" align="left" valign="top">n</td>
<td class="Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top"></td>
</tr>
</thead>
<tbody>
<tr class="First Toprule">
<td class="Lrule Rrule" align="left" valign="top">Placebo</td>
<td class="Rrule" align="left" valign="top">194</td>
<td class="Rrule" align="left" valign="top">0</td>
<td class="Rrule" align="left" valign="top">1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">25</td>
<td class="Rrule" align="left" valign="top">97</td>
<td class="Rrule" align="left" valign="top">0.08</td>
<td class="Rrule" align="left" valign="top">0</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">50</td>
<td class="Rrule" align="left" valign="top">245</td>
<td class="Rrule" align="left" valign="top">0.14</td>
<td class="Rrule" align="left" valign="top">0</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">100</td>
<td class="Rrule" align="left" valign="top">193</td>
<td class="Rrule" align="left" valign="top">0.09</td>
<td class="Rrule" align="left" valign="top">1</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">200</td>
<td class="Rrule" align="left" valign="top">139</td>
<td class="Rrule" align="left" valign="top">0.19</td>
<td class="Rrule" align="left" valign="top">1</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left" valign="top">400</td>
<td class="Rrule" align="left" valign="top">104</td>
<td class="Rrule" align="left" valign="top">0.36</td>
<td class="Rrule" align="left" valign="top">8.7</td>
</tr>
</tbody>
</table>
<p>Patients with both type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> and <span class="product-label-link" type="condition" conceptid="4195061" conceptname="Microalbuminuria">microalbuminuria</span> are at increased risk of developing persistent <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>. In a study of such patients taking INSPRA 200 mg, the frequencies of maximum serum potassium levels &gt;5.5 mEq/L were 33% with INSPRA given alone and 38% when INSPRA was given with enalapril.</p>
<p>Rates of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> increased with decreasing renal function. In all studies, serum potassium elevations &gt;5.5 mEq/L were observed in 10.4% of patients treated with INSPRA with baseline calculated creatinine clearance &lt;70 mL/min, 5.6% of patients with baseline creatinine clearance of 70 to 100 mL/min, and 2.6% of patients with baseline creatinine clearance of &gt;100 mL/min. <span class="Italics"> [See <a href="#i4i_section_id_66863df8-b8b2-46a7-8294-c1e32d7ae018">WARNINGS AND PRECAUTIONS (5.1)</a>.]</span></p>
<p><span class="Bold">Sodium:</span> Serum sodium decreased in a dose-related manner. Mean decreases ranged from 0.7 mEq/L at 50 mg daily to 1.7 mEq/L at 400 mg daily. Decreases in sodium (&lt;135 mEq/L) were reported for 2.3% of patients administered INSPRA and 0.6% of placebo-treated patients. </p>
<p><span class="Bold">Triglycerides:</span> Serum triglycerides increased in a dose-related manner. Mean increases ranged from 7.1 mg/dL at 50 mg daily to 26.6 mg/dL at 400 mg daily. Increases in triglycerides (above 252 mg/dL) were reported for 15% of patients administered INSPRA and 12% of placebo-treated patients.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span>:</span> Serum <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> increased in a dose-related manner. Mean changes ranged from a decrease of 0.4 mg/dL at 50 mg daily to an increase of 11.6 mg/dL at 400 mg daily. Increases in serum <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> values greater than 200 mg/dL were reported for 0.3% of patients administered INSPRA and 0% of placebo-treated patients. </p>
<p><span class="Bold">Liver Function Tests:</span> Serum <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span> (ALT) and gamma glutamyl transpeptidase (GGT) increased in a dose-related manner. Mean increases ranged from 0.8 U/L at 50 mg daily to 4.8 U/L at 400 mg daily for ALT and 3.1 U/L at 50 mg daily to 11.3 U/L at 400 mg daily for GGT. Increases in ALT levels greater than 120 U/L (3 times upper limit of normal) were reported for 15/2259 patients administered INSPRA and 1/351 placebo-treated patients. Increases in ALT levels greater than 200 U/L (5 times upper limit of normal) were reported for 5/2259 of patients administered INSPRA and 1/351 placebo-treated patients. Increases of ALT greater than 120 U/L and bilirubin greater than 1.2 mg/dL were reported 1/2259 patients administered INSPRA and 0/351 placebo-treated patients. <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic failure</span> was not reported in patients receiving INSPRA.</p>
<p><span class="Bold">BUN/Creatinine:</span> Serum creatinine increased in a dose-related manner. Mean increases ranged from 0.01 mg/dL at 50 mg daily to 0.03 mg/dL at 400 mg daily. Increases in blood urea nitrogen to greater than 30 mg/dL and serum creatinine to greater than 2 mg/dL were reported for 0.5% and 0.2%, respectively, of patients administered INSPRA and 0% of placebo-treated patients. </p>
<p><span class="Bold">Uric Acid:</span> Increases in uric acid to greater than 9 mg/dL were reported in 0.3% of patients administered INSPRA and 0% of placebo-treated patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c8550480-9ba5-4dde-8e0d-a5ad65ee202d"></a><a name="section-6.3"></a><p></p>
<h2>6.3 Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during postapproval use of INSPRA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p><span class="Italics">Skin: </span><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioneurotic edema</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_e09b17af-a954-4441-943f-944969816a00"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_56e7a51c-7887-43b2-bc11-270ad02fbc8e"></a><a name="section-7.1"></a><p></p>
<h2>7.1 CYP3A4 Inhibitors</h2>
<p class="First">Because eplerenone metabolism is predominantly mediated via CYP3A4, do not use INSPRA with drugs that are strong inhibitors of CYP3A4. <span class="Italics">[See <a href="#i4i_contraindications_id_3759c222-e2a9-4c12-9ab7-bb72e45246fa">CONTRAINDICATIONS (4)</a> and <a href="#i4i_pharmacokinetics_id_754212d6-10e5-4958-9297-c885f1e9bcc2">CLINICAL PHARMACOLOGY (12.3)</a>.]</span></p>
<p>In patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> taking moderate CYP3A4 inhibitors, reduce the starting dose of INSPRA to 25 mg once daily. <span class="Italics">[See <a href="#i4i_section_id_882d2422-4c98-4c3a-95f2-5494d2b8c08e">DOSAGE AND ADMINISTRATION (2.3,</a><a href="#i4i_section_id_a074659c-24b7-43cc-9f10-f0ed8f528c4f">2.4)</a> and <a href="#i4i_pharmacokinetics_id_754212d6-10e5-4958-9297-c885f1e9bcc2">CLINICAL PHARMACOLOGY (12.3)</a>.]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d62d10a2-6510-4fd4-b3e1-e3799a70a463"></a><a name="section-7.2"></a><p></p>
<h2>7.2 ACE Inhibitors and Angiotensin II Receptor Antagonists</h2>
<p class="First"><span class="Underline"><span class="Italics"><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> Post-<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></span></span></p>
<p>In EPHESUS <span class="Italics">[see <a href="#i4i_section_id_af8b703d-4a19-40aa-9128-58e7273e26dc">CLINICAL STUDIES (14.1)</a>]</span>, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists (ACEI/ARB). Rates of patients with maximum potassium levels &gt;5.5 mEq/L were similar regardless of the use of ACEI/ARB.</p>
<p><span class="Underline"><span class="Italics"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></span></span></p>
<p>In clinical studies of patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, the addition of INSPRA 50 to 100 mg to ACE inhibitors and angiotensin II receptor antagonists increased mean serum potassium slightly (about 0.09–0.13 mEq/L). In a study in diabetics with <span class="product-label-link" type="condition" conceptid="4195061" conceptname="Microalbuminuria">microalbuminuria</span>, INSPRA 200 mg combined with the ACE inhibitor enalapril 10 mg increased the frequency of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> (serum potassium &gt;5.5 mEq/L) from 17% on enalapril alone to 38%.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5a2c83d8-e1ff-49ea-b50e-786a4b6200ee"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Lithium</h2>
<p class="First">A drug interaction study of eplerenone with lithium has not been conducted. <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">Lithium toxicity</span> has been reported in patients receiving lithium concomitantly with diuretics and ACE inhibitors. Serum lithium levels should be monitored frequently if INSPRA is administered concomitantly with lithium.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b11782b9-98e1-49e1-91bd-9fee6183bd2a"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)</h2>
<p class="First">A drug interaction study of eplerenone with an NSAID has not been conducted. The administration of other potassium-sparing antihypertensives with NSAIDs has been shown to reduce the antihypertensive effect in some patients and result in severe <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Therefore, when INSPRA and NSAIDs are used concomitantly, patients should be observed to determine whether the desired effect on blood pressure is obtained and monitored for changes in serum potassium levels.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_595148f5-a0de-4cd7-b30e-540c8df4d443"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_195853d8-06f3-42b2-9819-e863ca025fb1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0025f13c-5725-4dc3-b59d-bd997c8ac023"></a><a name="section-8.1.1"></a><p></p>
<p class="First">Pregnancy Category B</p>
<p>There are no adequate and well-controlled studies in pregnant women. INSPRA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_ca9b839d-82b7-4219-b92f-5838b4e8ab3a"></a><a name="section-8.1.2"></a><p></p>
<p class="First"><span class="Underline"><span class="Italics">Teratogenic Effects</span></span></p>
<p>Embryo-fetal development studies were conducted with doses up to 1000 mg/kg/day in rats and 300 mg/kg/day in rabbits (exposures up to 32 and 31 times the human AUC for the 100 mg/day therapeutic dose, respectively). No teratogenic effects were seen in rats or rabbits, although decreased body weight in maternal rabbits and increased rabbit fetal resorptions and post-implantation loss were observed at the highest administered dosage. Because animal reproduction studies are not always predictive of human response, INSPRA should be used during pregnancy only if clearly needed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_cc20c30f-a32f-4ceb-8bf1-a46fa725c294"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">The concentration of eplerenone in human breast milk after oral administration is unknown. However, preclinical data show that eplerenone and/or metabolites are present in rat breast milk (0.85:1 [milk:plasma] AUC ratio) obtained after a single oral dose. Peak concentrations in plasma and milk were obtained from 0.5 to 1 hour after dosing. Rat pups exposed by this route developed normally. Because many drugs are excreted in human milk and because of the unknown potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_85b88a07-b0f4-4758-8e24-f38ced3f56d6"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">In a 10-week study of 304 hypertensive pediatric patients age 4 to 17 years treated with INSPRA up to 100 mg per day, doses that produced exposure similar to that in adults, INSPRA did not lower blood pressure effectively. In this study and in a 1-year pediatric safety study in 149 patients, the incidence of reported adverse events was similar to that of adults.</p>
<p>INSPRA has not been studied in hypertensive patients less than 4 years old because the study in older pediatric patients did not demonstrate effectiveness.</p>
<p>INSPRA has not been studied in pediatric patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_bd6c59c8-d1e2-44b9-b514-4adb22cac925"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4206a38b-cf37-4391-aab1-047b7975d6ed"></a><a name="section-8.4.1"></a><p></p>
<p class="First"><span class="Underline"><span class="Italics"><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> Post-<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></span></span></p>
<p>Of the total number of patients in EPHESUS, 3340 (50%) were 65 and over, while 1326 (20%) were 75 and over. Patients greater than 75 years did not appear to benefit from the use of INSPRA. <span class="Italics">[See <a href="#i4i_section_id_af8b703d-4a19-40aa-9128-58e7273e26dc">CLINICAL STUDIES (14.1)</a>.]</span></p>
<p>No differences in overall incidence of adverse events were observed between elderly and younger patients. However, due to age-related decreases in creatinine clearance, the incidence of laboratory-documented <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> was increased in patients 65 and older. <span class="Italics">[See <a href="#i4i_section_id_66863df8-b8b2-46a7-8294-c1e32d7ae018">WARNINGS AND PRECAUTIONS (5.1)</a>.]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4a79d748-9d7d-43e9-97ca-fbbeb73d6d88"></a><a name="section-8.4.2"></a><p></p>
<p class="First"><span class="Underline"><span class="Italics"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></span></span></p>
<p>Of the total number of subjects in clinical <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> studies of INSPRA, 1123 (23%) were 65 and over, while 212 (4%) were 75 and over. No overall differences in safety or effectiveness were observed between elderly subjects and younger subjects. </p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_a2bd5777-5e4b-4972-bdd7-826e61d9161f"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">No cases of human overdosage with eplerenone have been reported. Lethality was not observed in mice, rats, or dogs after single oral doses that provided C<span class="Sub">max</span> exposures at least 25 times higher than in humans receiving eplerenone 100 mg/day. Dogs showed <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>, <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">salivation</span>, and <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span> at a C<span class="Sub">max</span> 41 times the human therapeutic C<span class="Sub">max</span>, progressing to sedation and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> at higher exposures. </p>
<p>The most likely manifestation of human overdosage would be anticipated to be <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> or <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>. Eplerenone cannot be removed by hemodialysis. Eplerenone has been shown to bind extensively to charcoal. If symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> should occur, supportive treatment should be instituted. If <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> develops, standard treatment should be initiated.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_924f8636-b4a1-4546-a3b3-9f4631da79d7"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">INSPRA contains eplerenone, a blocker of aldosterone binding at the mineralocorticoid receptor. </p>
<p>Eplerenone is chemically described as Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-, γ-lactone, methyl ester, (7α,11α,17α)-. Its empirical formula is C<span class="Sub">24</span>H<span class="Sub">30</span>O<span class="Sub">6 </span>and it has a molecular weight of 414.50. The structural formula of eplerenone is represented below:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c7bc9486-8e61-4ba1-827f-2cd8c304b454&amp;name=c7bc9486-8e61-4ba1-827f-2cd8c304b454-01.jpg"></div>
<p>Eplerenone is an odorless, white to off-white crystalline powder. It is very slightly soluble in water, with its solubility essentially pH-independent. The octanol/water partition coefficient of eplerenone is approximately 7.1 at pH 7.0. </p>
<p>INSPRA for oral administration contains 25 mg or 50 mg of eplerenone and the following inactive ingredients: lactose, microcrystalline cellulose, croscarmellose sodium, hypromellose, sodium lauryl sulfate, talc, magnesium stearate, titanium dioxide, polyethylene glycol, polysorbate 80, and iron oxide yellow and iron oxide red. </p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_db273920-218e-4f4c-bcd2-3588c57f8d88"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_57ac546b-9f86-4a2b-9d01-bb694b2506f1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Eplerenone binds to the mineralocorticoid receptor and blocks the binding of aldosterone, a component of the renin-angiotensin-aldosterone-system (RAAS). Aldosterone synthesis, which occurs primarily in the adrenal gland, is modulated by multiple factors, including angiotensin II and non-RAAS mediators such as adrenocorticotropic hormone (ACTH) and potassium. Aldosterone binds to mineralocorticoid receptors in both epithelial (e.g., kidney) and nonepithelial (e.g., heart, blood vessels, and brain) tissues and increases blood pressure through induction of sodium reabsorption and possibly other mechanisms. </p>
<p>Eplerenone has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone on renin secretion. The resulting increased plasma renin activity and aldosterone circulating levels do not overcome the effects of eplerenone. </p>
<p>Eplerenone selectively binds to recombinant human mineralocorticoid receptors relative to its binding to recombinant human glucocorticoid, progesterone, and androgen receptors.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_754212d6-10e5-4958-9297-c885f1e9bcc2"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Eplerenone is cleared predominantly by cytochrome P450 (CYP) 3A4 metabolism, with an elimination half-life of 4 to 6 hours. Steady state is reached within 2 days. Absorption is not affected by food. Inhibitors of CYP3A4 (e.g., ketoconazole, saquinavir) increase blood levels of eplerenone.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1fe5c531-26e5-4d1d-a1d2-636451e3922c"></a><a name="section-11.2.1"></a><p></p>
<p class="First"><span class="Underline"><span class="Italics">Absorption and Distribution</span></span></p>
<p>Mean peak plasma concentrations of eplerenone are reached approximately 1.5 hours following oral administration. The absolute bioavailability of eplerenone is 69% following administration of a 100 mg oral tablet. Both peak plasma levels (C<span class="Sub">max</span>) and area under the curve (AUC) are dose proportional for doses of 25 to 100 mg and less than proportional at doses above 100 mg.</p>
<p>The plasma protein binding of eplerenone is about 50% and it is primarily bound to alpha 1-acid glycoproteins. The apparent volume of distribution at steady state ranged from 43 to 90 L. Eplerenone does not preferentially bind to red blood cells. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d8ab0f8c-dcf1-489f-9a17-9ada3b6ee57a"></a><a name="section-11.2.2"></a><p></p>
<p class="First"><span class="Underline"><span class="Italics">Metabolism and Excretion</span></span></p>
<p>Eplerenone metabolism is primarily mediated via CYP3A4. No active metabolites of eplerenone have been identified in human plasma. </p>
<p>Less than 5% of an eplerenone dose is recovered as unchanged drug in the urine and feces. Following a single oral dose of radiolabeled drug, approximately 32% of the dose was excreted in the feces and approximately 67% was excreted in the urine. The elimination half-life of eplerenone is approximately 4 to 6 hours. The apparent plasma clearance is approximately 10 L/hr.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a68c59ef-2112-4636-be7b-7be7b710d9a4"></a><a name="section-11.2.3"></a><p></p>
<p class="First"><span class="Underline"><span class="Italics">Age, Gender, and Race</span></span></p>
<p>The pharmacokinetics of eplerenone at a dose of 100 mg once daily has been investigated in the elderly (≥65 years), in males and females, and in Blacks. At steady state, elderly subjects had increases in C<span class="Sub">max</span> (22%) and AUC (45%) compared with younger subjects (18 to 45 years). The pharmacokinetics of eplerenone did not differ significantly between males and females. At steady state, C<span class="Sub">max</span> was 19% lower and AUC was 26% lower in Blacks. <span class="Italics">[See <a href="#i4i_section_id_a074659c-24b7-43cc-9f10-f0ed8f528c4f">DOSAGE AND ADMINISTRATION (2.4)</a> and <a href="#i4i_geriatric_use_id_bd6c59c8-d1e2-44b9-b514-4adb22cac925">USE IN SPECIFIC POPULATIONS (8.5)</a>.]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8571e007-6b98-49f5-b980-ed535ac6f5f8"></a><a name="section-11.2.4"></a><p></p>
<p class="First"><span class="Underline"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></span></p>
<p>The pharmacokinetics of eplerenone was evaluated in patients with varying degrees of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and in patients undergoing hemodialysis. Compared with control subjects, steady state AUC and C<span class="Sub">max</span> were increased by 38% and 24%, respectively, in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and were decreased by 26% and 3%, respectively, in patients undergoing hemodialysis. No correlation was observed between plasma clearance of eplerenone and creatinine clearance. Eplerenone is not removed by hemodialysis. <span class="Italics">[See <a href="#i4i_section_id_ded5d2d3-1376-4086-9d69-1776d629972f">WARNINGS AND PRECAUTIONS (5.3)</a>.]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_da55b8b7-5244-4c2d-8e22-63a614440730"></a><a name="section-11.2.5"></a><p></p>
<p class="First"><span class="Underline"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></span></p>
<p>The pharmacokinetics of eplerenone 400 mg has been investigated in patients with moderate (Child-Pugh Class B) <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> and compared with normal subjects. Steady state C<span class="Sub">max</span> and AUC of eplerenone were increased by 3.6% and 42%, respectively. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_db24dadd-5bc5-4f2c-8cc4-686a712d7d65"></a><a name="section-11.2.6"></a><p></p>
<p class="First"><span class="Underline"><span class="Italics"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span></span></span></p>
<p>The pharmacokinetics of eplerenone 50 mg was evaluated in 8 patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> (NYHA classification II–IV) and 8 matched (gender, age, weight) healthy controls. Compared with the controls, steady state AUC and C<span class="Sub">max</span> in patients with stable <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> were 38% and 30% higher, respectively.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e9cf2537-7428-4e43-b3fc-2d1e81b2af0c"></a><a name="section-11.2.7"></a><p></p>
<p class="First"><span class="Italics"><span class="Underline">Drug-Drug Interactions</span> [See <a href="#i4i_interactions_id_e09b17af-a954-4441-943f-944969816a00">DRUG INTERACTIONS (7)</a>.]</span></p>
<p>Eplerenone is metabolized primarily by CYP3A4. Inhibitors of CYP3A4 cause increased exposure <span class="Italics">[see <a href="#i4i_section_id_56e7a51c-7887-43b2-bc11-270ad02fbc8e">DRUG INTERACTIONS (7.1)</a>]</span>.</p>
<p>Drug-drug interaction studies were conducted with a 100 mg dose of eplerenone.</p>
<p>A pharmacokinetic study evaluating the administration of a single dose of INSPRA 100 mg with ketoconazole 200 mg two times a day, a strong inhibitor of the CYP3A4 pathway, showed a 1.7-fold increase in Cmax of eplerenone and a 5.4-fold increase in AUC of eplerenone. </p>
<p>Administration of eplerenone with moderate CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg once daily, saquinavir 1200 mg three times a day, fluconazole 200 mg once daily) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6-fold and AUC from 2.0- to 2.9-fold.</p>
<p>Grapefruit juice caused only a small increase (about 25%) in exposure.</p>
<p>Eplerenone is not an inhibitor of CYP1A2, CYP3A4, CYP2C19, CYP2C9, or CYP2D6. Eplerenone did not inhibit the metabolism of amiodarone, amlodipine, astemizole, chlorzoxazone, cisapride, dexamethasone, dextromethorphan, diclofenac, 17α-ethinyl estradiol, fluoxetine, losartan, lovastatin, mephobarbital, methylphenidate, methylprednisolone, metoprolol, midazolam, nifedipine, phenacetin, phenytoin, simvastatin, tolbutamide, triazolam, verapamil, and warfarin in vitro<span class="Italics">. </span>Eplerenone is not a substrate or an inhibitor of P-Glycoprotein at clinically relevant doses.</p>
<p>No clinically significant drug-drug <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> were observed when eplerenone was administered with cisapride, cyclosporine, digoxin, glyburide, midazolam, oral contraceptives (norethindrone/ethinyl estradiol), simvastatin, or warfarin. St. John's Wort (a CYP3A4 inducer) caused a small (about 30%) decrease in eplerenone AUC. </p>
<p>No significant changes in eplerenone pharmacokinetics were observed when eplerenone was administered with aluminum- and magnesium-containing antacids.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_fbcbf2d2-223f-4459-803a-a3edd06d5e5b"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_dce84290-9c00-4ffd-b573-58e921026556"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Eplerenone was non-genotoxic in a battery of assays including in vitro bacterial mutagenesis (Ames test in <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> </span>spp. and <span class="Italics">E. Coli</span>), in vitro mammalian cell mutagenesis (mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cells), in vitro chromosomal aberration (Chinese hamster ovary cells), in vivo rat bone marrow micronucleus formation, and in vivo/ex vivo unscheduled DNA synthesis in rat liver.</p>
<p>There was no drug-related tumor response in heterozygous P53 deficient mice when tested for 6 months at dosages up to 1000 mg/kg/day (systemic AUC exposures up to 9 times the exposure in humans receiving the 100 mg/day therapeutic dose). Statistically significant increases in benign <span class="product-label-link" type="condition" conceptid="4030041" conceptname="Thyroid nodule">thyroid tumors</span> were observed after 2 years in both male and female rats when administered eplerenone 250 mg/kg/day (highest dose tested) and in male rats only at 75 mg/kg/day. These dosages provided systemic AUC exposures approximately 2 to 12 times higher than the average human therapeutic exposure at 100 mg/day. Repeat dose administration of eplerenone to rats increases the hepatic conjugation and clearance of thyroxin, which results in increased levels of TSH by a compensatory mechanism. Drugs that have produced <span class="product-label-link" type="condition" conceptid="4030041" conceptname="Thyroid nodule">thyroid tumors</span> by this rodent-specific mechanism have not shown a similar effect in humans. </p>
<p>Male rats treated with eplerenone at 1000 mg/kg/day for 10 weeks (AUC 17 times that at the 100 mg/day human therapeutic dose) had decreased weights of seminal <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicles</span> and epididymides and slightly decreased fertility. Dogs administered eplerenone at dosages of 15 mg/kg/day and higher (AUC 5 times that at the 100 mg/day human therapeutic dose) had dose-related prostate <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span>. The prostate <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> was reversible after daily treatment for 1 year at 100 mg/kg/day. Dogs with prostate <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> showed no decline in libido, sexual performance, or semen quality. Testicular weight and histology were not affected by eplerenone in any test animal species at any dosage.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_45624429-b27e-4a37-a4e6-9353be65f73b"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_af8b703d-4a19-40aa-9128-58e7273e26dc"></a><a name="section-13.1"></a><p></p>
<h2>14.1 <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> Post-<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></h2>
<p class="First">The eplerenone post-<span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span> <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> efficacy and survival study (EPHESUS) was a multinational, multicenter, double-blind, randomized, placebo-controlled study in patients clinically stable 3–14 days after an <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span> (MI) with <span class="product-label-link" type="condition" conceptid="4047088" conceptname="Left ventricular systolic dysfunction">left ventricular dysfunction</span> (as measured by left ventricular <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> [LVEF] ≤40%) and either <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or clinical evidence of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> (CHF) (<span class="product-label-link" type="condition" conceptid="4194173" conceptname="Pulmonary congestion">pulmonary congestion</span> by exam or chest x-ray or S<span class="Sub">3</span>). Patients with CHF of valvular or congenital etiology, patients with unstable post-infarct angina, and patients with serum potassium &gt;5.0 mEq/L or serum creatinine &gt;2.5 mg/dL were to be excluded. Patients were allowed to receive standard post-MI drug therapy and to undergo revascularization by angioplasty or coronary artery bypass graft surgery.</p>
<p>Patients randomized to INSPRA were given an initial dose of 25 mg once daily and titrated to the target dose of 50 mg once daily after 4 weeks if serum potassium was &lt; 5.0 mEq/L. Dosage was reduced or suspended anytime during the study if serum potassium levels were ≥ 5.5 mEq/L. <span class="Italics">[See <a href="#i4i_section_id_36d8833d-3b8b-4482-8033-776f3a3b8532">DOSAGE AND ADMINISTRATION (2.1)</a>.]</span></p>
<p>EPHESUS randomized 6,632 patients (9.3% U.S.) at 671 centers in 27 countries. The study population was primarily white (90%, with 1% Black, 1% Asian, 6% Hispanic, 2% other) and male (71%). The mean age was 64 years (range, 22–94 years). The majority of patients had <span class="product-label-link" type="condition" conceptid="4194173" conceptname="Pulmonary congestion">pulmonary congestion</span> (75%) by exam or x-ray and were Killip Class II (64%). The mean <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> was 33%. The average time to enrollment was 7 days post-MI. Medical histories prior to the index MI included <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (60%), <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> (62%), <span class="product-label-link" type="condition" conceptid="4159131" conceptname="Dyslipidemia">dyslipidemia</span> (48%), angina (41%), type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> (30%), previous MI (27%), and CHF (15%). </p>
<p>The mean dose of INSPRA was 43 mg/day. Patients also received standard care including aspirin (92%), ACE inhibitors (90%), ß-blockers (83%), nitrates (72%), loop diuretics (66%), or HMG-CoA reductase inhibitors (60%).</p>
<p>Patients were followed for an average of 16 months (range, 0–33 months). The ascertainment rate for vital status was 99.7%.</p>
<p>The co-primary endpoints for EPHESUS were (1) the time to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> from any cause, and (2) the time to first occurrence of either cardiovascular (CV) mortality [defined as <span class="product-label-link" type="condition" conceptid="4317150" conceptname="Sudden cardiac death">sudden cardiac death</span> or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to progression of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> (CHF), <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, or other CV causes] or CV hospitalization (defined as hospitalization for progression of CHF, <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span>, or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>).</p>
<p>For the co-primary endpoint for <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> from any cause, there were 478 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> in the INSPRA group (14.4%) and 554 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> in the placebo group (16.7%). The risk of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> with INSPRA was reduced by 15% [hazard ratio equal to 0.85 (95% confidence interval 0.75 to 0.96; p = 0.008 by log rank test)]. Kaplan-Meier estimates of all-cause mortality are shown in Figure 1 and the components of mortality are provided in Table 9.<br> <br></p>
<p>Figure 1. Kaplan-Meier Estimates of All-Cause Mortality</p>
<div class="Figure"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c7bc9486-8e61-4ba1-827f-2cd8c304b454&amp;name=c7bc9486-8e61-4ba1-827f-2cd8c304b454-02.jpg"></div>
<a name="id_af5366cb-58ba-471e-8cc9-f14f4d2dce80"></a><table>
<caption><span>Table 9. Components of All-Cause Mortality in EPHESUS</span></caption>
<col align="left" width="25%">
<col align="center" width="20%">
<col align="center" width="20%">
<col align="center" width="20%">
<col align="center" width="15%">
<thead><tr class="Botrule First Last">
<td class="Lrule Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top">INSPRA<br>(N=3319)<br>n (%)</td>
<td class="Rrule" align="left" valign="top">Placebo<br>(N=3313)<br>n (%)</td>
<td class="Rrule" align="left" valign="top">Hazard<br>Ratio</td>
<td class="Rrule" align="left" valign="top">p-value</td>
</tr></thead>
<tbody>
<tr class="First Toprule">
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> from any cause</td>
<td class="Rrule" align="left" valign="top">478 (14.4)</td>
<td class="Rrule" align="left" valign="top">554 (16.7)</td>
<td class="Rrule" align="left" valign="top">0.85</td>
<td class="Rrule" align="left" valign="top">0.008</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">  CV <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span></td>
<td class="Rrule" align="left" valign="top">407 (12.3)</td>
<td class="Rrule" align="left" valign="top">483 (14.6)</td>
<td class="Rrule" align="left" valign="top">0.83</td>
<td class="Rrule" align="left" valign="top">0.005</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">  Non-CV <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span></td>
<td class="Rrule" align="left" valign="top">60 (1.8)</td>
<td class="Rrule" align="left" valign="top">54 (1.6)</td>
<td class="Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top"></td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left" valign="top">  Unknown or unwitnessed <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></td>
<td class="Rrule" align="left" valign="top">11 (0.3)</td>
<td class="Rrule" align="left" valign="top">17 (0.5)</td>
<td class="Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top"></td>
</tr>
</tbody>
</table>
<p>Most CV <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> were attributed to <span class="product-label-link" type="condition" conceptid="4132309" conceptname="Sudden death">sudden death</span>, acute MI, and CHF. </p>
<p>The time to first event for the co-primary endpoint of CV <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or hospitalization, as defined above, was longer in the INSPRA group (hazard ratio 0.87, 95% confidence interval 0.79 to 0.95, p = 0.002). An analysis that included the time to first occurrence of CV mortality and all CV hospitalizations (<span class="product-label-link" type="condition" conceptid="4021776" conceptname="Atrial rhythm">atrial arrhythmia</span>, angina, CV procedures, progression of CHF, MI, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmia</span>, or other CV causes) showed a smaller effect with a hazard ratio of 0.92 (95% confidence interval 0.86 to 0.99; p = 0.028). The combined endpoints, including combined all-cause hospitalization and mortality were driven primarily by CV mortality. The combined endpoints in EPHESUS, including all-cause hospitalization and all-cause mortality, are presented in Table 10.</p>
<a name="id_a28363f6-21f2-48c8-9dd5-bcb123ccd26a"></a><table>
<caption><span>Table 10. Rates of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> or Hospitalization in EPHESUS</span></caption>
<col align="left" width="50%">
<col align="center" width="25%">
<col align="center" width="25%">
<thead><tr class="Botrule First Last">
<td class="Lrule Rrule" align="center" valign="top">Event</td>
<td class="Rrule" align="left" valign="top">INSPRA<br>n (%)</td>
<td class="Rrule" align="left" valign="top">Placebo<br>n (%)</td>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>Co-Primary Endpoint.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First Toprule">
<td class="Lrule Rrule" align="left" valign="top">CV <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or hospitalization for progression of CHF, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, MI or <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmia</span><a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a>
</td>
<td class="Rrule" align="left" valign="top">885 (26.7)</td>
<td class="Rrule" align="left" valign="top">993 (30.0)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span></td>
<td class="Rrule" align="left" valign="top">407 (12.3)</td>
<td class="Rrule" align="left" valign="top">483 (14.6)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">  Hospitalization</td>
<td class="Rrule" align="left" valign="top">606 (18.3)</td>
<td class="Rrule" align="left" valign="top">649 (19.6)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">CV <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or hospitalization for progression of CHF, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, MI, <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="4021776" conceptname="Atrial rhythm">atrial arrhythmia</span>, angina, CV procedures, or other CV causes (PVD; <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>)</td>
<td class="Rrule" align="left" valign="top">1516 (45.7)</td>
<td class="Rrule" align="left" valign="top">1610 (48.6)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span></td>
<td class="Rrule" align="left" valign="top">407 (12.3)</td>
<td class="Rrule" align="left" valign="top">483 (14.6)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">  Hospitalization</td>
<td class="Rrule" align="left" valign="top">1281 (38.6)</td>
<td class="Rrule" align="left" valign="top">1307 (39.5)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">All-cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or hospitalization</td>
<td class="Rrule" align="left" valign="top">1734 (52.2)</td>
<td class="Rrule" align="left" valign="top">1833 (55.3)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">  <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span><a href="#footnote-3" class="Sup">*</a>
</td>
<td class="Rrule" align="left" valign="top">478 (14.4)</td>
<td class="Rrule" align="left" valign="top">554 (16.7)</td>
</tr>
<tr class="Botrule Last">
<td class="Lrule Rrule" align="left" valign="top">  Hospitalization</td>
<td class="Rrule" align="left" valign="top">1497 (45.1)</td>
<td class="Rrule" align="left" valign="top">1530 (46.2)</td>
</tr>
</tbody>
</table>
<p>Mortality hazard ratios varied for some subgroups as shown in Figure 2. Mortality hazard ratios appeared favorable for INSPRA for both genders and for all races or ethnic groups, although the numbers of non-Caucasians were low (648, 10%). Patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> without clinical evidence of CHF and patients greater than 75 years did not appear to benefit from the use of INSPRA. Such subgroup analyses must be interpreted cautiously.</p>
<div class="Warning">
<a name="id_c4b65e8e-b295-4836-9497-199c1067ebc7"></a><a name="section-13.1.1"></a><p></p>
<h3>Figure 2. Hazard Ratios of All-Cause Mortality by Subgroups</h3>
<p class="First"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c7bc9486-8e61-4ba1-827f-2cd8c304b454&amp;name=c7bc9486-8e61-4ba1-827f-2cd8c304b454-03.jpg"></p>
<p><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c7bc9486-8e61-4ba1-827f-2cd8c304b454&amp;name=c7bc9486-8e61-4ba1-827f-2cd8c304b454-04.jpg"></p>
<p><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c7bc9486-8e61-4ba1-827f-2cd8c304b454&amp;name=c7bc9486-8e61-4ba1-827f-2cd8c304b454-05.jpg"></p>
<p><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c7bc9486-8e61-4ba1-827f-2cd8c304b454&amp;name=c7bc9486-8e61-4ba1-827f-2cd8c304b454-06.jpg"></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="id_a2b83be3-0e50-43af-a9a3-f50abf0d4344"></a><a name="section-13.1.1"></a><p></p>
<p class="First">Analyses conducted for a variety of CV biomarkers did not confirm a mechanism of action by which mortality was reduced. </p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_33617a91-f383-4d7e-9018-78fbd92ebadf"></a><a name="section-13.2"></a><p></p>
<h2>14.2 <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> </h2>
<p class="First">The safety and efficacy of INSPRA have been evaluated alone and in combination with other antihypertensive agents in clinical studies of 3091 hypertensive patients. The studies included 46% women, 14% Blacks, and 22% elderly (age ≥65). The studies excluded patients with elevated baseline serum potassium (&gt;5.0 mEq/L) and elevated baseline serum creatinine (generally &gt;1.5 mg/dL in males and &gt;1.3 mg/dL in females). </p>
<p>Two fixed-dose, placebo-controlled, 8- to 12-week monotherapy studies in patients with baseline diastolic blood pressures of 95 to 114 mm Hg were conducted to assess the antihypertensive effect of INSPRA. In these two studies, 611 patients were randomized to INSPRA and 140 patients to placebo. Patients received INSPRA in doses of 25 to 400 mg daily as either a single daily dose or divided into two daily doses. The mean placebo-subtracted reductions in trough cuff blood pressure achieved by INSPRA in these studies at doses up to 200 mg are shown in Figures 3 and 4. <br> <br></p>
<div class="Figure"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c7bc9486-8e61-4ba1-827f-2cd8c304b454&amp;name=c7bc9486-8e61-4ba1-827f-2cd8c304b454-07.jpg"></div>
<div class="Figure"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c7bc9486-8e61-4ba1-827f-2cd8c304b454&amp;name=c7bc9486-8e61-4ba1-827f-2cd8c304b454-08.jpg"></div>
<p>Patients treated with INSPRA 50 to 200 mg daily experienced significant decreases in sitting systolic and diastolic blood pressure at trough with differences from placebo of 6–13 mm Hg (systolic) and 3–7 mm Hg (diastolic). These effects were confirmed by assessments with 24-hour ambulatory blood pressure monitoring (ABPM). In these studies, assessments of 24-hour ABPM data demonstrated that INSPRA, administered once or twice daily, maintained antihypertensive efficacy over the entire dosing interval. However, at a total daily dose of 100 mg, INSPRA administered as 50 mg twice per day produced greater trough cuff (4/3 mm Hg) and ABPM (2/1 mm Hg) blood pressure reductions than 100 mg given once daily. </p>
<p>Blood pressure lowering was apparent within 2 weeks from the start of therapy with INSPRA, with maximal antihypertensive effects achieved within 4 weeks. Stopping INSPRA following treatment for 8 to 24 weeks in six studies did not lead to adverse event rates in the week following withdrawal of INSPRA greater than following placebo or active control withdrawal. Blood pressures in patients not taking other antihypertensives rose 1 week after withdrawal of INSPRA by about 6/3 mm Hg, suggesting that the antihypertensive effect of INSPRA was maintained through 8 to 24 weeks. </p>
<p>Blood pressure reductions with INSPRA in the two fixed-dose monotherapy studies and other studies using titrated doses, as well as concomitant treatments, were not significantly different when analyzed by age, gender, or race with one exception. In a study in patients with low renin <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, blood pressure reductions in Blacks were smaller than those in whites during the initial titration period with INSPRA. </p>
<p>INSPRA has been studied concomitantly with treatment with ACE inhibitors, angiotensin II receptor antagonists, calcium channel blockers, beta blockers, and hydrochlorothiazide. When administered concomitantly with one of these drugs INSPRA usually produced its expected antihypertensive effects.</p>
<p>There was no significant change in average heart rate among patients treated with INSPRA in the combined clinical studies. No consistent effects of INSPRA on heart rate, QRS duration, or PR or QT interval were observed in 147 normal subjects evaluated for electrocardiographic changes during pharmacokinetic studies.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_a1289c6e-119e-4957-accf-3b63902953c7"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">INSPRA Tablets, 25 mg, are yellow diamond biconvex film-coated tablets. They are debossed with <span class="Italics">Pfizer </span>on one side and <span class="Italics">NSR</span> over <span class="Italics">25</span> on the other. They are supplied as follows:</p>
<a name="id_173f5d35-8507-4798-ba2a-8522707e0086"></a><table>
<col align="left" width="50%">
<col align="left" width="50%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="left" valign="top">NDC Number</td>
<td align="left" valign="top">Size</td>
</tr>
<tr class="Botrule Last">
<td align="left" valign="top">21695-797-90</td>
<td align="left" valign="top">Bottle of 90 tablets</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="i4i_storage_id_7c4a0c91-ada1-4431-ab6a-243c64bd05ee"></a><a name="section-14.1"></a><p></p>
<p class="First">Store at 25°C (77°F); excursions permitted to 15–30°C (59–86°F) [See USP Controlled Room Temperature].</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_d1ab8fc3-71ca-49ca-99fc-74d0920e8d2a"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Patients receiving INSPRA should be informed:</p>
<ul>
<li>Not to use strong CYP3A4 inhibitors, such as ketoconazole, clarithromycin, nefazodone, ritonavir, and nelfinavir.</li>
<li>Not to use potassium supplements or salt substitutes containing potassium without consulting the prescribing physician.</li>
<li>To call their physician if they experience <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, rapid or irregular heartbeat, lower extremity <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, or <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span>.</li>
<li>That periodic monitoring of blood pressure and serum potassium is important.</li>
</ul>
<p><span class="Italics">[See <a href="#i4i_contraindications_id_3759c222-e2a9-4c12-9ab7-bb72e45246fa">CONTRAINDICATIONS (4)</a>; <a href="#i4i_section_id_66863df8-b8b2-46a7-8294-c1e32d7ae018">WARNINGS AND PRECAUTIONS (5.1)</a>; and <a href="#i4i_interactions_id_e09b17af-a954-4441-943f-944969816a00">DRUG INTERACTIONS (7)</a>.]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0047aac0-2115-42f0-a0e7-810093c37eee"></a><a name="section-16"></a><p></p>
<p class="First"><img alt="Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c7bc9486-8e61-4ba1-827f-2cd8c304b454&amp;name=c7bc9486-8e61-4ba1-827f-2cd8c304b454-09.jpg"></p>
<p>LAB-0079-12</p>
<p>Repackaged by:</p>
<p><span class="Bold">Rebel Distributors Corp</span></p>
<p>Thousand Oaks, CA 91320</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_b2cf2623-cf88-437d-9968-71352b322a8d"></a><a name="section-17"></a><p></p>
<h1>Principal Display Panel</h1>
<p class="First"><img alt="Inspra 25mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c7bc9486-8e61-4ba1-827f-2cd8c304b454&amp;name=c7bc9486-8e61-4ba1-827f-2cd8c304b454-10.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>INSPRA 		
					</strong><br><span class="contentTableReg">eplerenone tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:21695-797(NDC:0025-1710)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>eplerenone</strong> (eplerenone) </td>
<td class="formItem">eplerenone</td>
<td class="formItem">25 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium lauryl sulfate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>talc</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>polyethylene glycol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>polysorbate 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ferric oxide yellow</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ferric oxide red</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">DIAMOND (biconvex) </td>
<td class="formLabel">Size</td>
<td class="formItem">7mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">Pfizer;NSR;25</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:21695-797-90</td>
<td class="formItem">90  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021437</td>
<td class="formItem">09/27/2002</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Rebel Distributors Corp
							(118802834)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Rebel Distributors Corp</td>
<td class="formItem"></td>
<td class="formItem">118802834</td>
<td class="formItem">RELABEL, REPACK</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>c7bc9486-8e61-4ba1-827f-2cd8c304b454</div>
<div>Set id: c7bc9486-8e61-4ba1-827f-2cd8c304b454</div>
<div>Version: 1</div>
<div>Effective Time: 20101228</div>
</div>
</div> <div class="DistributorName">Rebel Distributors Corp</div></p>
</body></html>
